{
    "over_18_start_BMI_over_27": {
        "header": "Verify Prescriber and Patient Documentation",
        "items": [
            {
                "label": "Document that member is actively enrolled in a weight-loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that the patient has an initial body mass index (BMI) ≥ 27 kg/m^2.",
                "validation": "An initial BMI of less than 27 kg/m^2 is unlikely to be approved."
            },
            {
                "label": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that the dose prescribed does not exceed 0.25mg in weeks 1-4, 0.5mg in weeks 5-8, 1mg in weeks 9-12 and 1.7mg in weeks 13-16.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            }
        ]
    },
    "over_18_start_BMI_over_30": {
        "header": "Verify Prescriber and Patient Documentation",
        "items": [
            {
                "label": "Document that member is actively enrolled in a weight-loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that the patient has an initial body mass index (BMI) ≥ 30 kg/m^2.",
                "validation": "An initial BMI of less than 30 kg/m^2 is unlikely to be approved."
            },
            {
                "label": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that the dose prescribed does not exceed 0.25mg in weeks 1-4, 0.5mg in weeks 5-8, 1mg in weeks 9-12 and 1.7mg in weeks 13-16.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            }
        ]
    },
    "over_18_first_continuation": {
        "header": "Prepare Patient Documentation",
        "items": [
            {
                "label": "Member has previously received medication via Centene benefit or is enrolled in a state and product with continuity of care regulations.",
                "validation": "Stop and submit a prior authorization following the criteria for start of therapy."
            },
            {
                "label": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Dose does not exceed 2.4 mg once weekly or a temporary dose reduction to 1.7mg for a maximum of 4 weeks.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that member has lost ≥ 5% of baseline body weight.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            }
        ]
    },
    "under_18_first_continuation": {
        "header": "Prepare Patient Documentation",
        "items": [
            {
                "label": "Member has previously received medication via Centene benefit or is enrolled in a state and product with continuity of care regulations.",
                "validation": "Stop and submit a prior authorization following the criteria for start of therapy."
            },
            {
                "label": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Dose does not exceed 1.7 mg once weekly.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that member has lost ≥ 5% of baseline BMI.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            }
        ]
    },
    "over_18_second_continuation": {
        "header": "Prepare Patient Documentation",
        "items": [
            {
                "label": "Member has previously received medication via Centene benefit or is enrolled in a state and product with continuity of care regulations.",
                "validation": "Stop and submit a prior authorization following the criteria for start of therapy."
            },
            {
                "label": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Dose does not exceed 2.4 mg once weekly or a temporary dose reduction to 1.7mg for a maximum of 4 weeks.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document member has lost weight and/or maintained at least 5% weight loss on therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            }
        ]
    },
    "under_18_second_continuation": {
        "header": "Prepare Patient Documentation",
        "items": [
            {
                "label": "Member has previously received medication via Centene benefit or is enrolled in a state and product with continuity of care regulations.",
                "validation": "Stop and submit a prior authorization following the criteria for start of therapy."
            },
            {
                "label": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Dose does not exceed 1.7mg.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document member has lost weight and/or maintained at least 5% weight loss on therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            },
            {
                "label": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            }
        ]
    },
    "under_18_initiation": {
        "header": "Verify Prescriber and Patient Documentation",
        "items": [
            {
                "label": "Document that member is actively enrolled in a weight loss program that involves a reduced calorie diet and increased physical activity adjunct to therapy",
                "validation": "Stop and contact provider to document this in the patient's chart."
            },
            {
                "label": "Document that the patient has an initial body mass index (BMI) in the 95th percentile or greater standardized for age and sex (obesity).",
                "validation": "Stop and contact provider to document this in the patient's chart."
            },
            {
                "label": "Document Wegovy is not prescribed concurrently with other semaglutide-containing products or any other GLP-1 receptor agonist(s).",
                "validation": "Stop and contact provider to document this in the patient's chart."
            },
            {
                "label": "Document that the dose prescribed does not exceed 0.25mg in weeks 1-4, 0.5mg in weeks 5-8, 1mg in weeks 9-12 and 1.7mg in weeks 13-16.",
                "validation": "Stop and contact provider to document this in the patient's chart. Add to your PA submission."
            }
        ]
    }
}